Product Description
Mechanisms of Action: ETa Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Percutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Medical University of Vienna
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hypertension, Pulmonary|Coronary Artery Disease|Myocardial Reperfusion Injury|Myocardial Infarction|Non-ST Elevated Myocardial Infarction
Phase 1: Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Bean ICRF clinical study | N/A |
Completed |
Vasculitis |
2020-01-01 |
|
| F1418-P | P1 |
Completed |
Heart Failure |
2019-03-31 |
|
| BQ-123 in CABG | P2 |
Terminated |
Coronary Artery Disease |
2015-10-15 |
|
| 2006-006778-11 | P2 |
Completed |
Myocardial Infarction |
2012-08-31 |